Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy.

[1]  F. Wenz,et al.  Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors , 2004, Cancer Gene Therapy.

[2]  H. Mizukami,et al.  Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice , 2003, Gene Therapy.

[3]  N. Muzyczka,et al.  Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. , 2002, Anticancer research.

[4]  F. Wenz,et al.  Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Y. Ikeda,et al.  Gene transduction efficiency in cells of different species by HIV and EIAV vectors , 2002, Gene Therapy.

[6]  P. Lønning,et al.  Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. , 2002, Human gene therapy.

[7]  R. Gibson,et al.  A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. , 2001, Human gene therapy.

[8]  H. Yeh,et al.  Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  P. Beard,et al.  Virus-mediated killing of cells that lack p53 activity , 2001, Nature.

[10]  I. Tohnai,et al.  Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector. , 2001, Oral oncology.

[11]  B. Byrne,et al.  CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.

[12]  H. Mizukami,et al.  γ-Rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells , 2001, Cancer Gene Therapy.

[13]  James M. Wilson,et al.  Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. , 2001, Human gene therapy.

[14]  N. Rainov,et al.  Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: Applications for prodrug-activating gene therapy , 2000, Cancer Gene Therapy.

[15]  B. Schiedlmeier,et al.  Differential expression of a recombinant adeno-associated virus 2 vector in human CD34+ cells and breast cancer cells , 2000, Cancer Gene Therapy.

[16]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[17]  B. Kleinschmidt-DeMasters,et al.  Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms , 2000, Cancer Gene Therapy.

[18]  J. Kleinschmidt,et al.  Superior gene transfer into solid tumour cells than into human mobilised peripheral blood progenitor cells using helpervirus-free adeno-associated viral vector stocks. , 1999, European journal of cancer.

[19]  T. Flotte,et al.  Safety and Biological Efficacy of an Adeno‐Associated Virus Vector–Cystic Fibrosis Transmembrane Regulator (AAV‐CFTR) in the Cystic Fibrosis Maxillary Sinus , 1999, The Laryngoscope.

[20]  D. Grimm,et al.  Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.

[21]  R. Ramesh,et al.  Clinical Protocol The Treatment of Malignant Mesothelioma with a Gene Modified Cancer Cell Line: A Phase I Study , 1998 .

[22]  R. Ramesh,et al.  The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. , 1998, Human gene therapy.

[23]  James M. Wilson,et al.  Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.

[24]  P. Ye,et al.  Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. , 1998, American journal of respiratory cell and molecular biology.

[25]  James M. Wilson,et al.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. , 1998, Human gene therapy.

[26]  A. Salvetti,et al.  Factors influencing recombinant adeno-associated virus production. , 1998, Human gene therapy.

[27]  S. Ponnazhagan,et al.  Adeno-Associated Virus Type 2-Mediated Gene Transfer: Correlation of Tyrosine Phosphorylation of the Cellular Single-Stranded D Sequence-Binding Protein with Transgene Expression in Human Cells In Vitro and Murine Tissues In Vivo , 1998, Journal of Virology.

[28]  T. Flotte,et al.  Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. , 1996, Gene therapy.

[29]  K. Tamayose,et al.  A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. , 1996, Human gene therapy.

[30]  G. Fishman,et al.  Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. , 1996, Gene therapy.

[31]  J. Peto,et al.  Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.

[32]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[33]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[34]  A. Bogdén,et al.  Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. , 1987, Cancer research.

[35]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[36]  E. Huang,et al.  Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. , 1983, Proceedings of the National Academy of Sciences of the United States of America.